July 28, 2022 10:29 AM EDT

Small Pennsylvania biotech lays off a fourth of its staff as it tries to navigate commercial landscape

Paul Schloesser

Associate Editor

Pennsylvania biotech Trevena put out word Thursday morning that it slashed 25% of its full-time staff and terminated a sales force agreement with Syneos, on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Small Pennsylvania biotech lays off a fourth of its staff as it tries to navigate commercial landscape

Paul Schloesser

Associate Editor

Sign up to read this article for free.

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Small Penn­syl­va­nia biotech lays off a fourth of its staff as it tries to nav­i­gate com­mer­cial land­scape

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Small Pennsylvania biotech lays off a fourth of its staff as it tries to navigate commercial landscape

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US